Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The investigators investigate the efficacy of non-opioid analgesics compared to placebo together with opioid therapy for cancer pain management.
Eligibility criteria
Qualifiers
Inpatient setting (discharge possible, if patient returns for End of Study Visit)
Diagnosis of metastatic or locally advanced cancer
Cancer pain as defined by IASP (International Association for the Study of Pain)
Cancer pain therapy with opioids indicated for pain management or start thereof at baseline (drug, dose, and route at treating physician's discretion)
Disqualifiers
History of allergy or allergy-like symptoms (bronchospasm, urticaria or severe cutaneous adverse reactions (SCARs)) or hypersensitivity to dipyrone (or other pyrazolones or pyrazolidines) or ibuprofen (or other Non-steroidal anti-inflammatory drug incl. acetylsalicylic acid)
Moderate to severe renal insufficiency (creatinine-eGFR (estimated Glomerular Filtration Rate) <45 ml/min)
Severe heart failure (New York Heart Association class III-IV)
Severe hepatic impairment (liver cirrhosis with ascites) or hepatic porphyria
Trial design
Treatments tested in this trial
- Metamizole
- Ibuprofen
- Placebo
Treatment groups
318 Participants
are divided into 3 treatment groupsSponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
Swiss GO Trial Group
Collaborator
Swiss National Science Foundation
Collaborator
Source ClinicalTrials.gov